Genetics mediate relation of birth weight to childhood IQ by Boomsma, D.I. et al.
VU Research Portal
Genetics mediate relation of birth weight to childhood IQ




DOI (link to publisher)
10.1136/bmj.323.7326.1426a
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Boomsma, D. I., van Beijsterveldt, C. E. M., Rietveld, M. J. H., Bartels, M., & van Baal, G. C. M. (2001). Genetics
mediate relation of birth weight to childhood IQ. British Medical Journal, 323, 1427.
https://doi.org/10.1136/bmj.323.7326.1426a
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 23. May. 2021
Monitoring clinical trials
Dissemination of decisions on interim
analyses needs wider debate
Editor—Lilford et al make a case that
interim analyses from randomised trials
should be shared with participants and doc-
tors and patients.1 These analyses should be
shared for the sake of freedom of infor-
mation and properly informed consent, as a
counterweight to paternalism, for the better
public understanding of uncertainty, and
regardless of drug regulatory or financial
considerations.1 But the authors stop short
of suggesting how to evolve the design of
randomised controlled trials so that future
patients and their doctors, in the light of
emerging information, might have more
choice than between 50:50 randomisation to
treatments A and B versus self determina-
tion to receive treatment A or B.
The consumer principle of random-
isation, which to my knowledge has not been
implemented since its enunciation in 1994,2
offers doctors and patients the option of
choosing one of three randomisation ratios,
such as 30:70 (uncertain or idiosyncratic
preference for B, yet willing to be randomised
if allocation is weighted in favour of B), 50:50
(absolute uncertainty or complete altruism),
or 70:30 (uncertain or idiosyncratic prefer-
ence for A, yet willing to be randomised if
allocation is weighted in favour of A).
Importantly, the choice of random-
isation strata is an additional patient covari-
ate that was not previously available;
comparison between treatments is unbiased
within the chosen randomisation stratum;
and how the choice of randomisation
stratum drifts after disclosure of interim data
is a measure of how those data were assimi-
lated by future patients and their doctors.
Data monitoring committees might even
decide to close one of the randomisation
strata, such as closing down 30:70 random-
isation if the interim data pointed moder-
ately convincingly in favour of A.
Not only should there be wider debate
about the dissemination to doctors and
patients of data monitoring committees’
decisions on interim analyses but there
should be wider debate about how those
decisions might affect both patient infor-
mation sheets and randomisation ratios.
Sheila M Bird senior statistician
MRC Biostatistics Unit, Cambridge CB2 2SR
sheila.bird@mrc-bsu.cam.ac.uk
1 Lilford RJ, Braunholtz D, Edwards S, Stevens A.
Monitoring clinical trials—interim data should be publicly
available. BMJ 2001;323:441-2. (25 August.)
2 Gore SM. The consumer principle of randomisation. Lan-
cet 1994;343:58.
Interim data should not be publicly
available
Editor—Lilford et al show little understand-
ing of the uncertainties involved in the assess-
ments of treatment effects.1 Few people are
aware of how much point estimates wander
about as both more patients and longer
follow up accrue in a randomised clinical
trial. This means that choices made by
patients on the basis of interim analyses are
unlikely to be “rational.” The trouble is that
when results go in a particular direction, the
natural instinct is to assume that they will
continue that way. This is why phrases appear
in papers such as, “there was a trend of 5% in
favour of treatment A, but this is not yet
significant,” implying that with more data it
will become so. Of course, it is just as likely
that future data will add up in the other direc-
tion so that the final result may be against
treatment A.
Data monitoring committees have been
implemented for good reasons that have
been well discussed in the past. The issues
involved in assessing results are not simple,
and involve not only statistical uncertainty
but issues such as length of follow up, inter-
nal consistency, baseline comparability, com-
pliance, adjustment for repeated tests, etc.2
The publication of interim results of ISIS-2
was for a particular subgroup where benefit
was clear.3 There are obviously circum-
stances where reporting certain results will
increase recruitment (for example, where
sceptical clinicians may decide to start enter-
ing patients because of apparently positive
effect), and others where they will reduce it
(for example, a slightly positive result might
make clinicians stop recruiting, with the
sceptical ones all stopping use of the
treatment and optimistic ones all deciding to
use it).
Rather than going backwards and
repeating the mistakes of the past, when
almost all trials were too small to give
definite answers—and even some of those
that apparently did, later turned out to be
misleading4—we should be concentrating on
the problem of lack of reporting of final
results for all randomised trials done. At
present the information available on a ques-
tion is often a biased subset owing to this
lack of publication.5
S M Richards statistician
CTSU, Radcliffe Infirmary, Oxford OX2 6HE
1 Lilford RJ, Braunholtz D, Edwards S, Stevens A.
Monitoring clinical trials—interim data should be publicly
available. BMJ 2001;323:441-2. (25 August.)
2 DeMets DL. Data monitoring and sequential analysis—an
academic perspective. J Acquir Immune Defic Syndr 1990;
3(suppl 2):S123-33.
3 ISIS-2 Steering Group. Intravenous streptokinase given
within 0-4 hours of onset of myocardial infarction reduced
mortality in ISIS-2. Lancet 1987;i:502.
4 Collins R, Peto R, Gray R, Parish S. Large-scale
randomized evidence: trials and overviews. In: Weatherall
DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of
medicine. 3rd ed. Oxford: Oxford University Press,
1996:21-32.
5 Dickersin K, Min YI, Meinert CL. Factors influencing pub-
lication of research results: follow-up of applications
submitted to two institutional research boards. JAMA
1992;263:374-8.
Caution may be warranted in releasing
interim trial data
Editor—Interpreting trial data even at the
end of a trial can be controversial and
difficult. Though there may be arguments in
some cases for releasing interim data,1
depending on the type of trial and strength
of findings, there are surely also strong argu-
ments for patient participants and trialists
keeping their nerve until all results are gath-
ered in. Why else do we employ statisticians
to undertake power calculations and pro-
vide recommendations of the cohort size
needed to produce reliable data?
Visualising what recruitment by
randomisation means has been facilitated by
likening it to the uneven and random distri-
Advice to authors
We prefer to receive all responses electronically,
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bution of raindrops on a surface before
complete coverage. My understanding is
that earlier trials in a series for review, and
interim results within a trial, can both be
misleading in the apparent direction of
results found.
Marketing pressure can also lead to pre-
mature stoppage of trials, where profit
rather than patients is the prime motivation
for the trials. This deprives not only “far
term” but also “near term” participants of
the satisfaction of finding out the long term
benefits and the overall health benefits of an
intervention already given to many near
term participants. This was the case in the
controversial stoppage of the American trial
of tamoxifen for the prevention of breast
cancer.2 It is interesting that the European
prevention trials did not follow suit; this was
perhaps because of a more convergent and
sensitive motivation of trialists and partici-
pants and joint determination to obtain long
term data despite apparent interim findings
in the United States.3
If the profession and patients collabo-
rate in designing trials with agreed long
term and short term objectives and aims,
agreed stopping rules, and procedures for
rapid and thorough dissemination of results
(including both professional and lay inter-
pretations) we might all derive full benefit
and satisfaction from staying the course
until the end. If patients are equal partners
in devising such contracts with profession-
als, by being on trial steering committees
and data monitoring committees, they will
have equal opportunity to make decisions
about whether or not to abandon the trial or
release interim data.
Many participants join trials for altruistic
reasons (23%) or trust in the doctor (21%),
not for what benefit they hope to get from
it.4 Why then adopt a shortcut process that
reduces the amount of learning, under-
standing, and benefit obtained from trials
with participants who will have received an
intervention that cannot be undone?
Hazel Thornton independent advocate for quality in
research and healthcare.
Saionara, 31 Regent Street, Rowhedge, Colchester
CO5 7EA
hazelcagct@aol.com
1 Lilford RJ, Braunholtz D, Edwards S, Stevens A.
Monitoring clinical trials—interim data should be publicly
available. BMJ 2001;323:441-2. (25 August.)
2 Fisher B. Current controversies in cancer. Tamoxifen for
the prevention of breast cancer: pro. Eur J Cancer
2000;36:142-50.
3 Thornton, H. Relationship of trial design to value of data
for patient? Eur J Cancer 2000;36:1585-6.
4 Jenkins V, Fallowfield L. Reasons for accepting or declining
to participate in randomised clinical trials for cancer
therapy. Br J Cancer 2000;82:1783-8.
Several points are contentious
Editor—I have four objections to Lilford et
al’s proposal for monitoring clinical trials.1
Firstly, I object to the philosophy. Any
people involved as subjects in a study are
already being used as a means, not an end.
The fact that they have volunteered for such a
role is admirable and puts them on a par with
firefighters and soldiers, who risk their lives
more than other members of society in a way
that benefits society. Concealing which treat-
ment a person is receiving is perfectly accept-
able and commonplace; therefore, perfect
disclosure is not an absolute requirement for
a morally justifiable trial. Trials are justified if
there is insufficient valid information for an
unbiased observer to make a decision.
Trials are shown to be valid when a well
designed, well conducted study is published
in an appropriate forum. Release of data
effectively replaces the last stage with one
that is less rigorous. This is not acceptable
because (apart from the danger of mistaken
conclusions) it is not what the researchers
and subjects agreed to.
Secondly, I object to practical aspects of
the proposal. Some studies do not have data
monitoring committees, and the committees
that do exist may have very different ideas.
Thus the scene is set for confusion on a
grand scale. Lilford et al suggest that there
could be guidelines. These are likely to be a
great deal more complicated than the
present situation. This proposal will also
greatly reduce the weight of properly
published evidence.
Thirdly, I object to the moral hazard. If I
am a researcher planning a trial in which it
will be difficult to recruit sufficient subjects to
gain certainty then I may be tempted to go
through the motions of applying for
funding, ethical approval, etc on the basis of
an unrealistically rapid recruitment sched-
ule. I will do this in the knowledge that the
data will get released anyway before the con-
clusion of the trial and a good trend will gain
approval for the treatment.
Lastly, I object to the authors’ misunder-
standing of the role of data monitoring
committees. I believe that their role is to stop
trials that are causing undue adverse events
and halt trials where the treatment effect has
been underestimated—that is, where the
number of subjects needed to show the
effect is really much lower than initially
thought. Inconclusive results at this stage
represent a well designed study.
David Parry online learning researcher
School of Information Technology, Business
Faculty, Auckland University of Technology,
Private Bag 92006, Auckland 1020, New Zealand
dave.parry@aut.ac.nz
1 Lilford RJ, Braunholtz D, Edwards S, Stevens A.
Monitoring clinical trials—interim data should be publicly
available. BMJ 2001;323:441-2. (28 August.)
Interim data are at least as important as
interim analyses
Editor—Lilford et al make several points
about the need to release interim results
from clinical trials.1 In discussing this,
however, they write of “interim data,” not
clarifying the separation between making
the results of interim analyses known and
releasing the actual interim data.
Researchers are always enormously
reluctant to release their data even after they
have published the results of their research.2
Given this, they are unlikely to consider
releasing the data that were the basis of any
interim analyses. The release of the actual
data, however, should be considered at least
as important as the release of interim
analyses.
Daniel Reidpath senior lecturer in social epidemiology
School of Health Sciences, Deakin University,
Burwood, VIC 3125, Australia
reidpath@deakin.edu.au
1 Lilford RJ, Braunholtz D, Edwards S, Stevens A.
Monitoring clinical trials—interim data should be publicly
available. BMJ 2001;323:441-2. (28 August.)
2 Reidpath DD, Allotey PA. Data sharing in medical research:
an empirical investigation. Bioethics 2001;15:125-34.
Latest data from START trial should be
made available
Editor—The opinions expressed by Lilford
et al regarding monitoring of clinical trials
are relevant to a current trial in the United
Kingdom of radiotherapy for breast cancer.1
The international standard fractionation
regimen consists of 50 Gy in 2 Gy fractions
on five days a week, but the evidence base for
this is tenuous. Many years ago it was
suggested from reviews of treatment of
advanced disease and skin metastases that
fewer larger fractions might be more
effective against breast cancer,2 but radio-
therapists have been reluctant to do this
because of fear of increased late morbidity.
In 1986 two oncology centres embarked
on a randomised trial comparing the stand-
ard 50 Gy with two schedules treating five
times a fortnight, 39 Gy and 42.9 Gy, both in
13 fractions. Interim data were presented in
1994, showing a significantly lower morbid-
ity for the 39/13 schedule: there was no dif-
ference in the rates of local recurrence of
carcinoma, but there had been few recur-
rences at that time.3 The trial closed in 1998
with 1400 patients enrolled. The schedules
were continued as one of the arms of the
multicentre standardisation of breast radio-
therapy (START) trial4 to obtain larger num-
bers and therefore more conclusive results.
The trial data were taken over by the data
monitoring committee and are being kept
secret on the basis that their publication
would prejudice recruitment to the trial. The
final results of the trial will not be known for
several years; meanwhile, 25 fractions
remains the standard.
The median follow up of these 1400
patients is now eight years. If there is still no
evidence of a significantly higher risk of
recurrence from the 13-fraction schedule
and the data were made publicly available,
radiotherapists could reasonably offer
women a course of treatment involving
fewer hospital attendances and with fewer
side effects rather than continuing to give
the standard 25 fractions while awaiting
results of the standardisation of breast
radiotherapy trial. Other patients with
cancer would also benefit from the conse-
quent reduction in the workload and
therefore shorter waiting lists in our hard
pressed radiotherapy departments. The
points raised by Lilford et al make a good
case that it is now time to publicise the latest
data from this trial.
J M Henk honorary consultant clinical oncologist,
Royal Marsden NHS Trust
76 The Crescent, Belmont, Surrey SM2 7BS
mhenk@doctors.org.uk
1 Lilford RJ, Braunholtz D, Edwards S, Stevens A.
Monitoring clinical trials—interim data should be publicly
available. BMJ 2001;323:441-2. (25 August.)
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2 Cohen L. Radiation response and recovery. In: Schwarz
EE, ed. The biological basis of radiation therapy. London: Pit-
man, 1966:208-16.
3 Yarnold JR, Bliss JM, Regan J, Broad B, Davison J,
Harrington G, et al. Randomised comparison of a
13-fraction schedule with a conventional 25-fraction
schedule of radiotherapy after local excision of early breast
cancer: preliminary analysis. Radiother Oncol 1994;32
(suppl 1):S101.
4 START Trial Management Group. Standardization of
breast radiotherapy (START) trial. Clin Oncol
1999;11:145-7.
Getting consent for necropsies
Perhaps we should seek consent to show
necropsies to students
Editor—Sayers and Mair highlight the
reasons for which hospital (consent) necrop-
sies are performed and for which clinicians
are now faced with the task of seeking
informed consent—to confirm the cause of
death, to answer diagnostic queries, and to
obtain and retain material for research and
teaching.1 Another key use of a necropsy,
not mentioned on the consent form, is in
undergraduate teaching. Many medical
students will encounter the necropsy during
their training, either witnessing the whole
procedure or as a demonstration of the
pathological findings of the procedure in
which organs and tissues are displayed (per-
haps with the patient’s body in the
background) before their return to the body.
Should explicit informed consent be
obtained to use necropsy in this way? The
short report by Westberg et al in the same
issue serves to highlight the importance of
obtaining consent for students to witness
invasive procedures such as a vaginal exam-
ination, even though most patients do not
object.2 Necropsy is no less invasive.
Whether patients and relatives would object
to a group of students viewing the body after
death is not known. It is established,
however, that “an important precondition
for good education of medical students is
that patients are prepared to participate in
training.”3 Failure to obtain consent denies
the autonomy of both the patient and the
relatives.
Some people argue that, once death has
occurred and the decision to allow a
necropsy has been taken, the worst is over
and therefore the presence of students at the
necropsy is of no consequence and does not
require consent. This denies relatives the
opportunity to be altruistic and know of the
benefits that come to students from the pro-
cedure. We should be as concerned that
consent is adequate as we are with who
obtains it.
Julian L Burton clinical lecturer in histopathology
Academic Unit of Pathology, Medical School,
University of Sheffield, Sheffield S10 2RX
j.l.burton@shef.ac.uk
1 Sayers GM, Mair J. Getting consent for autopsies:
who should ask what, and why? BMJ 2001;323:521.
(1 September.)
2 Westberg K, Lynøe N, Lalos A, Löfgren M, Sandlung M.
Getting informed consent from patients to take part in the
clinical training of students: randomised trial of two
strategies. BMJ 2001;323:488. (1 September.)
3 Lynøe N, Sandlung M, Westberg K, Duchek M. Informed
consent in clinical training–patient experiences and
motives for participating. Med Educ 1998;32:465-71.
Most relatives give consent once reasons
for necropsy are explained
Editor—As pathologists performing a large
number of perinatal autopsies, we read Say-
ers and Mair’s personal view with a mixture
of sadness and disbelief.1 We do not want to
increase the relatives’ and (in our case)
parents’ grief with detailed descriptions of
postmortem procedures. But current levels
of information available mean that most
already know the basics, and people want to
have a choice. Most of the detailed explana-
tions of what might happen to tissues and
organs at a postmortem examination have
been added to the consent form at the
insistence of parents’ pressure groups.
Teaching is essential for new doctors, all
of whom need to learn at least the basics of
pathology if they are going to be capable cli-
nicians. Most of the research projects requir-
ing postmortem tissues are clinicopatho-
logical studies. Almost all of them use tissues
that will be retained for histological diagno-
sis anyway. Because we now need consent to
retain even tissues used for diagnosis,
clinicians could explain that this retention
might help relatives in the future (including
in future pregnancies and similar diseases in
another member of the family).
Most pathologists retain full organs for
teaching and training or research only at the
specific request of a clinician. We are
surprised that some doctors are prepared to
give parents and relatives the consent form
and let them deal with it by themselves in
such a traumatic period.
Until recently there has not been much
training in communications skills in medical
schools, but surely opting out of the patient-
doctor relationship at this time is not an
answer. The main reasons for a hospital
necropsy are to explain to the relatives what
happened to the patient and to help the cli-
nicians understand the disease process. It is
not the pathologist who primarily benefits
from a necropsy.
In our experience, most parents (and
most hospital postmortem examinations are
performed in perinatal cases) agree to the
requests in the consent form for a postmor-
tem examination once the reasons are
explained to them, especially by a doctor
they have met and trust. We are surprised
that Sayers and Mair find it acceptable for a
person whom the parents or relatives have
never met before to come and talk to them
at this time or at the time of the necropsy.
If clinicians want to discuss any aspect of
the necropsy, including the reasons for
requests other than diagnosis, we are all
happy to help.
Irene Scheimberg senior lecturer in paediatric and
perinatal pathology
i.b.scheimberg@mds.qmw.ac.uk
Alan W Bates consultant histopathologist
Abigail Lee senior house officer
Royal London Hospital, London E1 1BB
1 Sayers GM, Mair J. Getting consent for autopsies:
who should ask what, and why? BMJ 2001;323:521.
(1 September.)
Bereavement teams might ask for consent
for necropsy
Editor—As we work in histopathology we
have a keen interest in the process of hospi-
tal necropsy and getting consent for necrop-
sies.1 We can assure all clinicians that
pathologists across the United Kingdom are
acutely aware of the Alder Hey scandal, and
caution abounds within the profession.
Custom does indeed dictate that clini-
cians involved in patient care approach rela-
tives to seek consent for necropsy, but,
although the new consent forms may be
overly detailed, the amount of information
one is required to give relatives in order to
obtain genuinely informed consent has not
changed. The total time needed to achieve
consent has not altered greatly, although a
small amount of time is required to take the
relatives through the layout of what can be a
slightly confusing form.
The process of asking relatives whether
they want some parts of the body or some
specific organs left intact is unhelpful to them
and also to the pathologist. Indeed, incom-
plete necropsies, without the option to take
samples for microscopic examination or toxi-
cology tests, often fail to give the definitive
answers desired; the utility of doing only a
partial necropsy should often be questioned.
It is also unrealistic, when one considers the
logistics involved, to suggest that pathologists
should consult families (in the middle of the
procedure) when something interesting is
found that may require the results of
histological tests to diagnose fully.
As Sayers and Mair state, doctors are
expected to be sensitive, but therefore why do
they propose that a pathologist—not previ-
ously known to the patient or family and
therefore less able to empathise with their
situation—should approach relatives for con-
sent?1 Staffing issues should also be consid-
ered. Clinicians are stretched for time, but
moving the onus to pathology, which
currently has the biggest consultant staffing
crisis of any specialty, would only make
matters worse.
Given the changes in the medicolegal
climate, new, detailed consent forms are a
necessity. Maybe the best way forward is to
consider employing specially trained
bereavement teams to deal with this process.
M Holbrook registrar, histopathology
G Morgan senior house officer, histopathology
morganrandg@aol.com
Leicester Royal Infirmary, Leicester LE1 5WW
1 Sayers GM, Mair J. Getting consent for autopsies:
who should ask what, and why? BMJ 2001;323:521.
(1 September.)
Genetics mediate relation of
birth weight to childhood IQ
Editor—Matte et al reported an association
between birth weight and childhood IQ.1 To
control for confounding by maternal and
family factors they examined this relation in
sibships of the same sex and found an
association between birth weight and IQ
Letters
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within male sibships. This association may
be mediated by genetic factors.
The impact of genetic factors on this
association can be determined through the
investigation of birth weight and IQ in twin
pairs. Differences within dizygotic twin pairs
are a function of both genetic and
non-genetic factors, whereas differences
within monozygotic twin pairs are almost
completely caused by non-genetic factors.2 If
genetic factors mediate the association
between birth weight and IQ it is expected
that for dizygotic twin pairs the association
between intrapair differences in birth weight
and IQ is positive, while for monozygotic
twin pairs no association is expected.
In a Dutch longitudinal twin study the
association between birth weight and IQ was
measured in 170 twin pairs of the same sex.3
Birth weight was obtained with a question-
naire, administered to the mother after the
birth of the twins. Full IQ was obtained at ages
5, 7, and 10 with the revised Amsterdam child
intelligence test (RAKIT), a Dutch intelli-
gence battery, and at age 12 with the Wechsler
intelligence scale for children.
Comparison between cotwins with low-
est and highest birth weights showed that
the dizygotic twins with the lowest birth
weight had a lower IQ than their cotwin with
the highest birth weight at ages 5 to 10
(table). This difference was not seen in the
monozygotic twin pairs. Mean IQ was the
same for the twins with the lowest and high-
est birth weights. When twin pairs with a
gestational age of < 37 weeks were excluded
the results were similar. We also determined
the association of intrapair differences in
birth weight and IQ. At ages 7 and 10 this
association was positive in dizygotic twin
pairs (r = 0.29, P = 0.01; r = 0.27, P = 0.02)
but not in monozygotic twin pairs
(r = − 0.02, P = 0.88; r = 0.01, P = 0.91).
Our results suggest that genetic factors
mediate part of the association between
birth weight and childhood IQ, at least until
age 10. We found an association between
intrapair differences in birth weight and IQ
in dizygotic twin pairs. As twin pairs share
influences such as prenatal factors, socio-
economic status, parental smoking, and
parental age, the influence of these
confounders is negligible. In addition, in
monozygotic twin pairs, in whom intrapair
differences reflect only environmental influ-
ences, the association between intrapair
differences in birth weight and IQ is absent.
D I Boomsma professor
DI.Boomsma@fppl.psy.vu.nl
C E M van Beijsterveldt assistant professor
M J H Rietveld PhD student
M Bartels PhD student
G C M van Baal associate professor
Vrije Universiteit, Department of Biological
Psychology, 1081 BT, Amsterdam, Netherlands
1 Matte TD, Bresnahan M, Begg MD, Susser E. Influence of
variation in birth weight within normal range and within
sibships on IQ at age 7 years: cohort study. BMJ
2001;323:310-4. (11 August.)
2 Philips DI. Twins studies in medical research: can they tell
us whether diseases are genetically determined? Lancet
1993;341:1008-9.
3 Boomsma DI, van Baal GCM. Genetic influences on child-
hood IQ in 5- and 7-year old Dutch twins. Dev Neuropsychol
1998;14:115-26.
Quality of care for people with
dementia
Change in attitude is needed
Editor—Are readers surprised by Ballard et
al’s findings that nursing homes are failing
the needs of patients with dementia?1
Probably not, especially if they spend any
time in nursing homes either as a healthcare
professional or as a relative or friend.
Ballard et al’s conclusion that strategies
to improve joint working between the agen-
cies to provide integrated specialist services
sounds good, but surely it’s the day to day
care that’s failing people with dementia. Of
course they need specialised services, but
they need compassion, an understanding of
their needs, appropriate activities, and
human interaction. These things need time
and a special kind of staff who enjoy working
with elderly people with challenging
problems.
Until relatively recently we were also
failing children with severe learning dis-
abilities. Now we understand these children’s
needs and rights to education, choice, and
social interaction. People who work with
these children are highly regarded in our
society, if not well financially remunerated. It
seems to me that until we start to apply the
same ethos of care to our elderly people that
we apply to our ill and disabled children we
will continue to fail them. We must always
remember that one day it may be us sitting
in that chair with no way of communicating
our distress.
Joan Scott higher professional fellow
Department of General Practice, Glasgow G12 0RR
joani.scott@btinternet.com
1 Ballard C, Fossey J, Chithramohan R, Howard R, Burns A,
Thompson P, et al. Quality of care in private sector and
NHS facilities for people with dementia: cross sectional
survey. BMJ 2001;323:426-7. (25 August.)
Dementia care mapping is inadequate
tool for research
Editor—Ballard et al draw conclusions
from observing residents’ activities in estab-
lishments providing care for people with
dementia that few specialist professionals
would disagree with: that standards are poor
and must be raised.1 Their methodology,
however, is potentially misleading if service
providers use the dementia care index alone
as an indicator of improved quality of care.
Dementia care mapping measures the
subjective experience of the service user
across three dimensions (type of activity,
degree of comfort, and time). Standardisa-
tion of data is achieved through thorough
accredited training, and the dementia care
index is derived from aggregation of
observations. Typically in our experience,
the activity is observed during the working
hours of people other than nurses and
rarely during early mornings, evenings, and
nights.
The paper refers to a standardised six
hours of mapping in each home in the study
but fails to extrapolate general and relevant
data on the quality of the services provided
across a 168 hour week. When longitudinal
studies have used the dementia care index as
Full IQ score at ages 5, 7, 10, and 12 of cotwins with lowest and highest birth weights in dizygotic and monozygotic twin pairs. Values are means (SD)











Birth weight (g) 2451 (436) 2804 (380) 0 2337 (427) 2545 (404) 0
Full IQ score:
Age 5 77 99.4 (12.9) 102.6 (12.8) 0 81 102.9 (12.8) 105.3 (13.4) 0.01
Age 7 72 99.0 (13.9) 103.2 (14.5) 0 73 104.0 (15.1) 103.7 (14.0) 0.83
Age 10 75 104.1 (13.9) 106.8 (13.9) 0 75 108.0 (16.2) 107.6 (16.5) 0.70
Age 12 73 98.6 (12.8) 100.3 (14.1) 0.22 75 100.2 (13.9) 101.27 (12.5) 0.20
Gestational age >36 weeks
Birth weight (g) 2550 (436) 2935 (333) 0 0 2535 (383) 2745 (353) 0
Full IQ score:
Age 5 59 99.5 (12.7) 103.0 (11.9) 0 45 101.6 (11.7) 104.7 (13.3) 0.02
Age 7 56 98.2 (14.5) 104.0 (14.7) 0 42 101.1 (14.3) 101.3 (14.1) 0.90
Age 10 58 104.6 (13.7) 108.3 (12.2) 0 42 106.7 (15.1) 105.4 (16.1) 0.34
Age 12 56 98.7 (13.2) 101.73 (13.2) 0 41 97.4 (12.4) 98.3 (11.6) 0.39
*IQ differences between cotwins with lowest and highest birth weights were tested with paired t tests.
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a methodological tool it has been to
measure the effect of training, empower-
ment, or other external dynamic factor
rather than overall quality of life or care. As
experienced managers and clinicians in
acute and long stay dementia wards, we
would be concerned if the quality of care
provided could be generalised from obser-
vations in such a period.
Increasing use should not be made of
data from dementia care mapping as a com-
parative indicator of quality of care in units
or for individuals. Incorporating a less
subjective measure of quality of life to the
study design, such as the dementia specific
quality of life scale2 or a user oriented
framework,3 would have added to the
validity of the authors’ findings.
Marshall’s editorial highlights several
structural and process deficits in places
where dementia care is provided.4 Externally
set standards, expectations, resources, and
training are all important in improving care.
Each of these factors needs to be incorpo-
rated into the scrutiny of care quality for
such research to have quantitative conclu-
sions. Dementia care mapping can only
presage qualitative discussions within teams.
We would be concerned if care homes
began to market their services on the basis
of a six hour observed rating, but this may be
an outcome of such research methods.
Clinicians and service managers need to
clarify the minimum standards for care
homes for older people.5 The tools we use to
develop and audit the quality of care must
comprehensively reflect the multitude of
needs of people with dementia.
Chris Edwards senior nurse manager
Oxfordshire Mental Healthcare NHS Trust,
Littlemore Hospital, Oxford OX4 4XN
edwards.chris@btconnect.com
Chris Fox senior lecturer
Kent Institute of Medical Sciences, Folkestone
Health Centre, Folkestone, Kent CT20 1JY
1 Ballard C, Fossey J, Chithramohan R, Howard R, Burns A,
Thompson P, et al. Quality of care in private sector and
NHS facilities for people with dementia: cross sectional
survey. BMJ 2001;323:426-7. (25 August.)
2 Gonzalez-Salvador T, Lysetkos CG, Baker A, Hovanec L,
Roques C, Brandt J, Steele C. Quality of life in dementia
patients in long term care. Int J Geriatr Psychiatry
2000;15:181-9.
3 Dabbs C. What do people with dementia most value in life?
J Dementia Care 1999 July/August 16-19.
4 Marshall M. The challenge of looking after people with
dementia. BMJ 2001;323:410-1. (25 August.)
5 Department of Health. Care homes for older people. National
minimum standards. London: Stationery Office, 2001.
Registries charting epidemiological trends
and benchmark outcomes are required
Editor—We have some reservations about
the use of dementia care mapping (used in
the paper by Ballard et al) for benchmarking
the quality of care of people with dementia.1
A fundamental problem is that health and
social services have failed to chart the needs
for the care of dementia and in consequence
service commissioning has been inadequate.
Ballard et al’s report finds both the health
service and the independent sector deficient.
It is particularly damning for a health service
that has had over 50 years to plan investment
in services for people with dementia.
Care homes are the subject of intense
policy development and escalating regula-
tion. Commissioning, torn between “best
practice” and “value,” is dominated by finan-
cial constraints. Marshall, in the accompany-
ing editorial, rightly promotes creatively
designed environments for care,2 but the
necessary finance is not forthcoming.
We have seen a recent phenomenon in
referrals for placement in a care home of
frail elderly people currently in acute hospi-
tal beds. Assessment by care home staff
shows these people to have dementia and to
be commonly sedated, in an apparent act of
containment. A rationale for this seems to be
health authority rules that registered mental
nurses must supervise residents with
dementia in nursing care homes. An
irreconcilable shortage of registered mental
nurses has led to this regrettable “diagnostic
denial.” Assessments seem to say more about
the needs of commissioners than the needs
of the person needing placement.
Whole systems of integrated care have
been proposed.3 A recent report from the
King’s Fund highlighted the poor pay of
care workers compared, for example, with
supermarket employees.4 Combine this with
inadequate commissioning of basic and
continuing training of care staff and lack of
career progression for staff in dementia care
and Ballard et al’s observations become
entirely understandable.
Good dementia care does exist in both
the NHS and the independent sector, but
usually as a result of enthusiastic champions
rather than design. The dementia care
literature reports many anecdotes of inad-
equacy and too infrequent evidence of inno-
vation. Inclusive registries are required that
chart epidemiological trends and bench-
mark outcomes. Such an approach would
inform investment as well as regulation for
dementia care, putting dementia on an equi-
table basis with conditions such as heart
disease and cancer.
Clive Bowman medical director
Graham Stokes consultant in mental health
BUPA Care Services, Horsforth, Leeds LS18 4UP
bowmanc@bupa.com
1 Ballard C, Fossey J, Chithramohan R, Howard R, Burns A,
Thompson P, et al. Quality of care in private sector and
NHS facilities for people with dementia: cross sectional
survey. BMJ 2001;323:426-7. (25 August.)
2 Marshall M. The challenge of looking after people with
dementia. BMJ 2001;323:410-1. (25 August.)
3 Royal College of Physicians. The health and care of older
people in care homes. A comprehensive interdisciplinary
approach. London: RCP, 2000.
4 Henwood M. Future imperfect. Report of the King’s Fund care
and support worker inquiry. London: King’s Fund, 2001.
Teenage pregnancy is not a
public health problem
Editor—We agree with Smith and Pell’s
interpretation of their own and others’
results that first teenage pregnancies are not
associated with adverse outcomes, but we
disagree with their conclusion that the asso-
ciations they found between second teenage
pregnancy and risk of preterm delivery and
stillbirth indicate causation.1 The most likely
explanation is a combination of inadequate
control for socioeconomic position, which
the authors concede, and differences in the
interval between pregnancies among teen-
age compared with older mothers.
Differences in pregnancy spacing can-
not be rejected as an explanation, as the
authors attempt to do, without its impact in
this study being assessed. Furthermore, the
authors do not consider the possible impact
of differences in antenatal care between
pregnant teenagers and older women in any
of their analyses.
Health professionals should not accept
without challenge the myth that teenage
pregnancy is an important public health
problem in the way that these authors do.
There is no biological reason to suggest that
having a baby before the age of 20 is associ-
ated with ill health. It is increasingly
common for women to delay their first birth
until they are in their 30s; the mean age at
first birth for married women in England
and Wales was 29.3 in 1999. This is despite
the increased risk of chromosomal abnor-
malities and complications of pregnancy in
this age group.
Women having babies in their 30s and
40s are not labelled a public health
problem, and neither are women who have
problems conceiving, even though their
babies have an increased risk of perinatal
death.2 This so called public health problem
of teenage pregnancy is really a reflection of
what is considered to be socially, culturally,
and economically acceptable in the United
Kingdom.
Current policy in the United Kingdom
aims, firstly, to halve the conception rate of
the under 18s and set a downward trend in
the rate for under 16s by 2010 and, secondly,
to achieve a reduction in the risk of long
term social exclusion of teenage parents and
their children.3 We would argue that the sec-
ond of these goals is the appropriate public
health aim, and yet most action is likely to be
geared towards the first. A primary care
group in Bristol received funds from the
local health authority’s inequalities budget
to undertake work towards achieving the
first of these targets only.4
Teenage pregnancy is not a public
health problem; the cumulative effect of
social and economic exclusion on the health
of mothers and their babies, whatever their
age, is.
Debbie Lawlor lecturer in epidemiology and public
health medicine
D.A.Lawlor@bristol.ac.uk
Mary Shaw senior research fellow
Department of Social Medicine, University of
Bristol, Bristol BS8 2PR
Sarah Johns PhD student
School of Geographical Sciences, University of
Bristol, Bristol BS8 1SS
1 Smith GCS, Pell JP. Teenage pregnancy and risk of adverse
perinatal outcomes associated with first and second births:
population based retrospective cohort study. BMJ
2001;323:476-9. (1 September.)
2 Draper ES, Kurinczuk JJ, Abrams KR, Clarke M.
Assessment of separate contributions to perinatal mor-
tality of infertility history and treatment; a case-control
analysis. Lancet 1999;353:1746-9.
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3 Social Exclusion Unit. Teenage pregnancy. London: Station-
ery Office, 1999.
4 Velleman G, Williams E. The role of the primary care
group in promoting health. In: Scriven A, Orme J, eds.
Health promotion, professional perspectives. New York:
Palgrave (in association with Open University), 2001:
43-51.
National service frameworks
Framework’s claim that GPs should
devote more time to preventing coronary
heart disease needs scrutiny
Editor—The national service framework
for coronary heart disease states that “addi-
tional coronary heart disease prevention
activities . . . will consume time, effort and
resource. Primary care teams will have to
give careful consideration to how resources
used on lower value and lower priority
activities might be redirected to the high
priority, high value treatments identified.”1
The framework does not give any evidence
justifying the claim that traditional services
are low value or quantify the benefit of high
value treatments.
I estimated the maximum benefit of
activities aimed at reducing mortality by
considering patients registered with a
typical singlehanded general practitioner in
northwest Lancashire because the area has
the highest mortality from coronary heart
disease in the United Kingdom.2 3 Each year
such a practice registers about 22 births and
deaths.3 Since the framework’s objective is
to reduce mortality among those under 75 I
estimated the maximum impact of the
activities by assessing how many more
patients would survive to 75 if all of them
were provided.1 I used an actuarial life table
method to prepare several survival curves
for an annual birth cohort of 22 patients,4
obtaining mortality and population data
from the public health common dataset3
and the Japanese Embassy (S Onishi,
personal communication, 1999). I chose
Berkshire’s coronary heart disease rate
because it is the lowest in the United King-
dom, and Japan’s because it is the lowest in
the world.
The figure shows that if all cause
mortality remains at 1996 levels and
national service framework activities have
no impact on coronary heart disease, 13.5 of
the 22 patients dying each year will celebrate
their 75th birthday; if coronary heart disease
is eradicated, 15.5 patients will do so; if
northwest Lancashire’s coronary heart dis-
ease mortality is reduced to that of Japan,
15; and if the mortality is reduced to that of
Berkshire, 14.
The maximum benefit that could result
from all national service framework activi-
ties seems to be that two extra patients
could survive to 75 annually, but this is
unobtainable because the services are
unlikely to eradicate coronary heart disease.
Furthermore, since Lancastrians are
unlikely to adopt the lifestyle of the
Japanese, fewer than 1.5 extra patients can
be expected to survive to 75. Lancastrians
could acquire the behaviours and social and
medical advantages of those in Berkshire, in
which case an extra 0.5 patient could
survive to 75 annually.
As general practitioner services are only
a small proportion of all the framework
activities the impact that a general prac-
titioner could make will be modest. I believe
that the framework’s claim that general
practitioners should devote more time to
coronary heart disease prevention and less
to traditional services is not compelling.
A M Rouse senior lecturer
Department of Public Health and Epidemiology,
University of Birmingham, Birmingham B15 2TT
A.M.Rouse@bham.ac.uk
1 Department of Health. National service frameworks for coron-
ary heart disease; standard four. London: DoH, 2000.
2 Doll R. The causes of cancer: quantitative estimates of avoidable
risks of cancer. Oxford: Oxford University Press, 1981.
3 Institute of Public Health. Public health common data set. Vol
III. Surrey: IPH, 1996.
4 Mausner JS, Kramer S. Epidemiology: an introductory text.
2nd ed. Philadelphia: Saunders, 1985.
National service framework for older
people is worth a try
Editor—More than three pages of critical
letters from senior figures threaten to blow
the national service framework for older
people into oblivion.1 Isn’t it strange that
such a quiet and sober document has gener-
ated such a response?
The document will do much for older
people if we use it well. It is fearless in draw-
ing attention to ageism and encourages us
to consider older people as individuals. It
looks at the systems that have developed in
health care in recent years, and says that old
people are not well served by being
required to receive the same approaches
as younger people with simpler health
problems.
The framework considers some of the
most common problems of old age, looking
at the contributions of history, lifestyle, and
family and recognising the differing and
complementary strengths of social care, pri-
mary care, and secondary care. It encour-
ages us to work across boundaries of mental
and physical health and always to seek to
promote good practice and achieve best
health for older people.
This is a good attempt to help us do
better; it should be given a chance.
David Jolley director
Kate Read executive director
Dementia Plus West Midlands, Wolverhampton
WV4 4PQ
dementiaplus.wm@whc-tr.wmids.nhs.uk
1 Correspondence. New beginning for care for elderly
people? BMJ 2001;323:337-40. (11 August.)
Don’t GPs have to be good
clinicians any more?
Editor—I agree that the selection of
doctors is far from perfect, but I am
concerned that the emphasis shown by Pat-
terson et al on key competencies for general
practitioner registrars in Career focus will
encourage the selection of politically correct
candidates with little clinical acumen.1
Of the 11 key competencies quoted,
only one, remarkably, related to clinical
skills. The other 10 competencies, all
management related, could easily have been
condensed into two or three. Aren’t pro-
fessional integrity, coping with pressure,
and empathy and sensitivity personal
attributes in the same way as motivation and
flexibility are? Aren’t organising and plan-
ning skills, legal and political awareness,
problem solving, and communication skills
also part of team involvement and
managing others? And what on earth is
conceptual thinking? In this new world of
general practitioner training I am already
feeling deficient.
I see a similar trend in my own hospital’s
training days in the vocational training
scheme, and I am concerned that the
general practitioners of tomorrow will
become clinically weakened as a result. I
have noticed a similar trend in my own spe-
cialty, where the exit exam is now dominated
by management and research, with only a
quarter of it given to clinical acumen.
Surely clinical skills and expertise are
more important now than ever; this
worrying trend must be checked before
it takes over the undergraduate curriculum
as well.
Adrian Fogarty consultant in accident and emergency
medicine
Royal Free Hospital, London NW3 2QG
afogarty@btinternet.com
1 Patterson F, Lane P, Ferguson E, Norfolk T. Competency
based selection system for general practitioner registrars
[career focus]. BMJ 2001;323(7311, classified section):2.
(1 September.)





































All cause mortality but with Berkshire's CHD rates
All cause mortality but with Japan's CHD rates
All cause mortality but with CHD eradicated
Survival curves for patients registered with typical
singlehanded general practitioner in northwest
Lancashire (1996 data). CHD=coronary heart
disease. NW=northwest Correspondence submitted electronically
is available on our website
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